T2 Biosystems Expects FY23 Total Sepsis & Related Product Rev Of $9.5M-$10.5M, Representing Growth Of 13-5% YoY; Sees Prelim Q2 Total Revenue Of $2M
Portfolio Pulse from Benzinga Newsdesk
T2 Biosystems expects its FY23 total sepsis and related product revenue to be between $9.5M and $10.5M, representing a YoY growth of 13-5%. The company also anticipates preliminary Q2 total revenue of $2M.
July 12, 2023 | 12:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
T2 Biosystems expects a YoY growth of 13-5% in FY23 total sepsis and related product revenue, and a preliminary Q2 total revenue of $2M.
The company's projected increase in revenue for FY23 and the expected Q2 revenue indicates a positive financial outlook, which could potentially lead to a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100